Tempest Therapeutics, Inc.
Index- P/E- EPS (ttm)-11.14 Insider Own1.10% Shs Outstand7.17M Perf Week-6.81%
Market Cap21.64M Forward P/E- EPS next Y-4.16 Insider Trans- Shs Float5.70M Perf Month-43.26%
Income-31.40M PEG- EPS next Q-0.92 Inst Own31.90% Short Float4.06% Perf Quarter-44.42%
Sales- P/S- EPS this Y74.20% Inst Trans-7.40% Short Ratio0.70 Perf Half Y-62.50%
Book/sh4.10 P/B0.53 EPS next Y-7.60% ROA-44.50% Target Price22.50 Perf Year-83.61%
Cash/sh- P/C- EPS next 5Y- ROE-80.00% 52W Range2.00 - 41.00 Perf YTD-58.52%
Dividend- P/FCF- EPS past 5Y58.10% ROI- 52W High-94.66% Beta0.47
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low9.50% ATR0.33
Employees17 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)38.86 Volatility13.43% 12.29%
OptionableNo Debt/Eq0.00 EPS Q/Q81.80% Profit Margin- Rel Volume0.04 Prev Close2.29
ShortableYes LT Debt/Eq0.51 EarningsMar 29 AMC Payout- Avg Volume330.21K Price2.19
Recom1.70 SMA20-14.10% SMA50-24.92% SMA200-66.23% Volume13,204 Change-4.37%
Jun-09-22 08:00AM  
Jun-06-22 04:05PM  
May-26-22 04:57PM  
May-13-22 08:00AM  
Apr-27-22 10:01AM  
Apr-08-22 01:00PM  
Mar-29-22 04:00PM  
Mar-10-22 08:00AM  
Mar-08-22 04:30PM  
Feb-09-22 08:00AM  
Nov-18-21 08:00AM  
Nov-12-21 07:00AM  
Nov-10-21 04:05PM  
Nov-09-21 08:00AM  
Nov-08-21 08:00AM  
Oct-01-21 08:00AM  
Sep-20-21 08:00AM  
Sep-13-21 08:00AM  
Sep-09-21 04:01PM  
Aug-12-21 04:01PM  
Aug-09-21 08:00AM  
Jul-09-21 08:00AM  
Jul-01-21 04:00PM  
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Woiwode ThomasDirectorApr 29Buy2.362,118,6445,000,0002,118,644May 03 05:49 PM
Dubensky Thomas W.PresidentJan 07Buy4.782,0009,560113,343Jan 11 06:36 PM
Whiting SamuelChief Medical OfficerJan 06Buy4.801,7008,1681,901Jan 10 06:37 PM